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Key points 
• Serum elevated GGT is associated with vascular disease outcomes, metabolic 
syndrome, diabetes, cancer, chronic kidney disease, fractures, dementia, and 
total mortality. 
• Biological mechanisms postulated for these relationships include oxidative 
stress, inflammation, and underlying fatty liver. 
• Limited data suggests GGT is unlikely to improve disease risk prediction and 
data on the causal relevance of GGT to these outcomes are lacking. 
• GGT assays may have the potential to aid in the identification of individuals 
who need further evaluation of risk factors for adverse outcomes.  
• Further work is needed to understand the pathophysiological mechanisms that 
underlie the associations and implications for clinical practice. 
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Abstract 
Gamma-glutamyltransferase, is a liver enzyme which is located on the plasma membranes of 
most cells and organ tissues, but more commonly in hepatocytes and is routinely used in 
clinical practice to help indicate liver injury and as a marker of excessive alcohol 
consumption. Among the liver enzymes, important advances have especially been made in 
understanding the physiological functions of GGT. The primary role of GGT is the 
extracellular catabolism of glutathione, the major thiol antioxidant in mammalian cells, which 
plays a relevant role in protecting cells against oxidants produced during normal metabolism; 
GGT, therefore plays an important role in cellular defence. Beyond its physiological 
functions, circulating serum GGT has been linked to a remarkable array of chronic conditions 
and diseases, which include nonalcoholic fatty liver disease, vascular and non-vascular 
diseases, as well as mortality outcomes. This review summarizes the available 
epidemiological and genetic evidence for the associations between GGT and these adverse 
outcomes; the postulated biologic mechanisms underlying these associations; outlines areas 
of outstanding uncertainty; and the implications for clinical practice. 
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The liver plays a major role in metabolism and has a number of functions including protein 
synthesis, glycogen storage, lipid metabolism, and secretion of acute phase proteins in 
response to inflammation. Plasma liver biochemistry tests are groups of clinical laboratory 
blood assays widely used in the clinic to give information about the state of a patient's liver; 
and assays for gamma-glutamyltransferase (GGT), alanine aminotransferase (ALT), aspartate 
aminotransferase (AST), and alkaline phosphatase (ALP) are the most commonly used for 
this purpose. Circulating levels of these enzymes are markers of liver injury, associated with 
cellular integrity, or with conditions linked to the biliary tract and can be used to measure the 
severity of hepatic inflammation, cellular injury, or obstruction (1). They are commonly used 
to identify patients with liver diseases, monitor the course and severity of these diseases, and 
the effect of therapies (2). There have been important advances in the understanding of the 
physiological functions of these liver enzymes and several epidemiological associations have 
been reported. Among the liver enzymes, research has largely focused on GGT. Beyond its 
physiological functions, circulating serum GGT has been linked to several adverse outcomes, 
which include nonalcoholic fatty liver disease (NAFLD), vascular and non-vascular diseases, 
as well as mortality outcomes. This review aims to summarize available information on the 
physiological role of GGT; evidence on the epidemiological and genetic associations between 
GGT and these outcomes; evidence on the postulated biologic mechanisms underlying these 
associations; outlines areas of outstanding uncertainty; and implications for clinical practice. 
 
Occurrence, physiology, and functions of GGT 
Gamma-glutamyltransferase, originally called gamma-glutamyl transpeptidase, was first 
adopted as a liver biochemistry test in the 1960s and 1970s (3). It is a glycoprotein with a 
molecular weight of 68,000 daltons and consist of two proteins - a larger and smaller chain 
with molecular weights of 46,000 and 22,000 daltons respectively (1). It is located on the 
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plasma membranes of most cells and organ tissues, but more commonly hepatocytes (3). 
Gamma-glutamyltransferase is also found in the extracellular fluid attached to α and β 
lipoproteins (4) and albumin carrier molecules (5). It has recently been reported that GGT is 
made up of four fractions namely big-GGT (b-GGT), medium-GGT (m-GGT), small-GGT 
(s-GGT), and free-GGT (f-GGT), with each having its own molecular weight and distinct 
physiochemical properties (6, 7). Human GGT genes are located on chromosome 22 (8, 9), 
with related sequences that are non-functional or represent pseudogenes on chromosomes 18, 
19, and 20 (9). There are seven or more GGT genes in humans, but only one of these gives 
rise to a complete and functional protein (10). The active GGT enzyme is coded by GGT1 on 
chromosome 22 (11). Gamma-glutamyltransferase activity is significantly genetically 
determined and its heritability has been estimated to range between 50 to 77% in adults (12-
15). It has been suggested that half of the genetic variance in GGT is shared by ALT and 
AST. Though the same genes influence GGT activity across age and sex, their relative 
contribution to the variation in its activity differs in males and females and across age (15). 
 
The primary role of GGT is the extracellular catabolism of glutathione, the major thiol 
antioxidant in mammalian cells, which enables precursor amino acids to be assimilated and 
re-utilized for intracellular synthesis of glutathione (3). Glutathione plays a relevant role in 
protecting cells against oxidants produced during normal metabolism. The reaction that GGT 
catalyzes is the transfer of a glutamyl residue (linked through glutamate’s gamma carboxylic 
acid to an amine or to another amino acid) to an acceptor (3), therefore maintaining adequate 
levels of glutathione. Gamma-glutamyltransferase is also involved in the transfer of amino 
acids across cell membranes (16) and metabolism of leukotriene (17). Liver injury or 
blockage of bile ducts can cause accumulation of GGT in the liver and secretion of excess 
GGT into circulation. In clinical practice, raised circulating GGT values are routinely and 
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widely used to help indicate potential hepatic or biliary disease and as a biologic marker of 
excessive alcohol intake (3). A number of demographic and physiological factors, which 
shade into risk factors for disease; affect GGT values, making the definition of a reference 
range very complicated (3). Common factors influencing the reference range include sex, 
pregnancy, childbirth, race, smoking, oral contraceptive use, and exercise. The reference 
range for GGT activity is similar across ages, though there are significant gender differences, 
with males having higher values than females (18) (Figure 1). The gender difference in GGT 
activity is most likely physiologic and has been attributed to the effect of sex hormones. The 
recommended cut-off for the upper normal limit of GGT has been set at an average of 51 U/L 
for males and 33 U/L for females (19). Common causes of elevated GGT activity include 
liver disease, obesity, excessive alcohol consumption, medications (such as phenytoin, 
phenobarbital, furosemide, and heparin), congestive cardiac failure, and smoking (20, 21). 
Younger females and pregnancy are associated with decreased GGT activity, whilst 
postmenopausal women and those taking oral contraceptives have higher GGT activity closer 
to that of men (3). Black populations have higher values compared with Caucasian 
populations. Over the past two decades, significant progress has been made in understanding 
the physiological functions of GGT and evidence for several epidemiological associations has 
been uncovered.  
 
Epidemiological associations of GGT with risk markers for disease 
The multi-functional role of the liver in metabolism and inflammation suggests that complex 
relationships are likely to exist between the liver markers and several biochemical, metabolic, 
lipid, or inflammatory factors. Though GGT has a high heritability (13-15), its activity is 
highly variable, with the variability significantly affected by various environmental factors 
such as body mass index (BMI), alcohol consumption, and age (14). Gamma-
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glutamyltransferase has been demonstrated to be associated with several lifestyle, 
biophysical, and biochemical factors, majority of which are risk factors for vascular and non-
vascular disease. Positive associations with age, BMI, waist circumference, alcohol 
consumption, smoking, heart rate, blood pressure, serum levels of glucose, ferritin, uric acid, 
and lipids [triglycerides, total cholesterol, and low-density lipoprotein (LDL) cholesterol] 
have been demonstrated (22, 23), whereas inverse associations have been observed with high-
density lipoprotein cholesterol, physical activity, and lung function (3). Gamma-
glutamyltransferase is also known to correlate with several dietary factors such as coffee 
consumption, fruit and meat intake, as well as vitamin status (24). Studies have consistently 
demonstrated that BMI has the strongest association with GGT compared with other risk 
markers, with GGT increasing progressively across all classes of BMI (22, 25-27). Indeed, 
GGT has been shown to have a causal association with BMI, as well as with fasting insulin 
(28, 29). The strong relationships between GGT and several risk markers have been attributed 
to common genetic loci that affect GGT activity and these risk markers (13). 
 
Relationship between GGT and NAFLD 
Nonalcoholic fatty liver disease is a common clinical condition characterised by hepatic 
steatosis with varying degrees of necroinflammation and fibrosis and which develops in the 
absence of substantial alcohol intake (30). It spans a range of conditions from simple hepatic 
steatosis to nonalcoholic steato-hepatitis and cirrhosis (30, 31) and is regarded as the hepatic 
component of the metabolic syndrome (MetS) (32-34). Nonalcoholic fatty liver disease has 
reached epidemic proportions and it is emerging as the most common cause of chronic liver 
disease in the developed world (30, 35, 36).  The global prevalence of NAFLD has been 
estimated to be around one-third of the general population (37), with estimates varying 
between 70-90% in individuals who are obese or have type 2 diabetes mellitus (T2DM) (38-
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40). Its diagnosis is based on (i) imaging techniques (i.e., ultrasonography, CT scan, or MRI) 
confirming the presence of fat infiltration of the liver, and/or liver biopsy showing steatosis in 
at least 5% of hepatocytes(41) and (ii) exclusion of other liver diseases of other aetiology 
such as significant alcohol consumption or drug-induced liver disease, autoimmune or viral 
hepatitis, and cholestatic or metabolic/genetic liver disease (42). It is the most common cause 
for unexplained elevated liver enzymes including the transaminases and GGT (43-46). The 
most commonly observed biochemical pattern in NAFLD is increased levels of 
transaminases, with ALT exceeding levels of AST.(47) Elevated ALT has frequently been 
used as a biochemical surrogate for NAFLD diagnosis; however, it is not uncommon to 
diagnose NAFLD in patients with normal ALT levels using ultrasonography or histology (36, 
48). Elevated GGT activity has less frequently been used as a surrogate biomarker for 
NAFLD. 
 
Obesity is one of the most important factors in the development of NAFLD. Fall and 
colleagues in their recent Mendelian randomization study (29), provided novel evidence for a 
causal effect of adiposity (as measured by BMI) on GGT and ALT; with suggestions that 
elevated activity of these liver enzymes caused by an increased BMI, are likely to be related 
to NAFLD. Nonalcoholic fatty liver disease is strongly associated with obesity as well as 
several cardiometabolic risk factors (38, 39), MetS, T2DM (49), and mortality, with CVD 
being the most common cause of death among patients with NAFLD (46, 50). Independent 
associations have also been demonstrated for other adverse outcomes such as heart failure 
(HF) (51), cardiac arrhythmias (52, 53), hepatocellular cancer (HCC) (54), chronic kidney 
disease (CKD) (55), and cognitive decline (56). For these reasons, it has been hypothesized 
that NAFLD may be the underlying cause for the associations of elevated GGT with several 
vascular and non-vascular outcomes. 
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Prospective associations of GGT with vascular, non-vascular, and all-cause mortality 
outcomes 
Cardiovascular disease 
Gamma-glutamyltransferase has been implicated in CVD development with epidemiologic 
evidence suggesting greater CVD risk with higher serum GGT activity. Although interest in 
GGT as an emerging risk factor for CVD goes back at least several decades, further research 
was stimulated with the publication of the first systematic review and meta-analysis by Fraser 
and colleagues (57) (Table and Figure 2). They reported an independent and positive 
association between GGT and risk of CVD. However, despite the evidence and the 
publication of additional studies, there were still uncertainties regarding the shape and nature 
of the association between GGT and CVD risk. In 2014, our group published an updated 
meta-analysis comprising 20 studies (1,054,181 participants and 15,194 events) and which 
included a dose-response analysis. The findings confirmed a positive and independent 
association between GGT and CVD, which was consistent with a log-linear relationship 
(Table and Figure 2) (58). Positive and independent associations between GGT and CVD 
mortality have also been demonstrated (59, 60). Given the somewhat diverse aetiology of 
different vascular events such as stroke and coronary heart disease, it was uncertain whether 
the effect of GGT on these cause-specific vascular outcomes may differ. However, several 
studies have shown GGT to be positively and independently associated with both stroke and 
CHD outcomes with similar magnitudes of effect (57, 58, 61). Given the independent 
association of higher GGT levels with increased cardiovascular risk, there has been an 
evolving debate on whether adding information on GGT to current CVD risk prediction 
algorithms might be associated with improvements in the ability to predict CVD beyond 
established cardiovascular risk factors (1, 62, 63). Whiles some studies have reported a 
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marginal improvement in CVD risk prediction (64, 65), a recent large-population based 
cohort analysis by our group has shown that addition of GGT to conventional CVD risk 
factors is unlikely to improve prediction of first-ever cardiovascular events (66). 
 
Several mechanistic pathways for the increased cardiovascular risk associated with elevated 
levels of GGT have been postulated. Though at normal values, GGT counteracts oxidative 
stress by making cysteine available for regeneration of intracellular glutathione, recent 
evidence has also demonstrated that serum GGT values within the normal reference range are 
associated with promotion of atherosclerosis. Pro-oxidant and pro-inflammatory activities 
have been proposed to underlie this process (67-69). At normal values, serum GGT catalyzes 
LDL oxidation in vitro; it initially catalyzes the degradation of extracellular glutathione, the 
major thiol intracellular antioxidant in the body. Glutathione is hydrolyzed by GGT into 
glutamate and a cysteinyl-glycine dipeptide. Glutamate is subsequently recycled inside the 
cell, producing additional glutathione. The cysteinyl-glycine dipeptide acts as a strong 
reducing agent of iron on the cellular membrane and in the extracellular space, resulting in 
the development of free radical species (1) which may cause oxidation of LDL, which is 
believed to participate in other processes such as cell proliferation and development of 
atheroma within the vascular endothelial wall (1, 67). Gamma-glutamyltransferase also 
mediates interconversion of the glutathione-containing inflammatory mediator leukotriene C4 
into leukotriene D4 (70). It has also been reported that GGT may be directly involved in 
atheromatous plaque formation (68). Indeed, GGT activity has been found within cerebral, 
carotid, and coronary plaques, co-localizing with oxidised lipids and foam cells (71, 72). Of 
the four GGT fractions identified, only b-GGT is found within atherosclerotic plaques and 
has been suggested to be the fraction involved in the pathogenesis of CVD (7). In addition, 
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GGT may be linked to CVD risk via underlying NAFLD, which is a major risk factor for 
CVD (73, 74) and commonly associated with increased serum GGT activity. 
 
The consistent findings of a linear and independent association between GGT and CVD risk 
is suggestive of causality, but this requires robust evidence from randomized controlled trials. 
However, trials to enable causal inferences may be unlikely, as several pharmacological 
agents (such as insulin sensitizers and antioxidants) that modify GGT activity also influence 
levels of other liver enzymes and lipid factors (75). Mendelian randomization (MR) studies of 
genetic variants specifically related to GGT may provide another route to assess causality 
(76). There is evidence to suggest that the GGT1 locus, which is the main protein-coding 
gene for GGT, may be specific for GGT activity (77, 78) and therefore variants within this 
locus might be valid instrumental variables for MR studies. Till date, the causal relevance of 
GGT to CVD has been difficult to assess as these variants explain only a small fraction of the 
variability in levels of GGT, in addition to their pleiotropic effects on other phenotypic traits 
(79). Larger Genome Wide Association Studies (GWASs) may help uncover new variants to 
explain the missing heritability in GGT activity. Next generation DNA sequencing may also 
provide an opportunity to identify rare genetic variants which have large effects on GGT 
activity. 
 
Heart failure 
The first population-based prospective study of GGT activity and HF risk was reported in 
2005 by Ruttman and colleagues (20). This study comprising of 163,944 participants and 162 
HF cases, reported a positive and independent association between GGT and HF risk. Three 
more studies prospective studies (80-82) were published after this study. To provide a better 
indication of the relevance of GGT to HF, given the small number of HF cases included in 
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previous studies; our group has recently conducted a detailed assessment of the association of 
GGT activity with risk of HF using a prospective cohort of 1,780 men and also performed a 
pooled analysis of available published prospective evidence on the associations in one 
comprehensive analysis. Given that GGT exhibits high within-person variability which has 
been recently reported (83),  we also corrected for “regression dilution bias” (84). Our meta-
analysis of five studies indicated that a two-fold increase in usual GGT values was associated 
with approximately 40% higher risk of HF (Table and Figure 2) (85). Whether GGT has the 
potential to be used in the identification of individuals at high risk of HF is yet to be 
elucidated. Dhingra and colleagues reported a marginal improvement in HF risk prediction on 
addition of GGT to a standard risk engine (80). 
 
Postulated pathways underlying the relationship between elevated GGT values and increased 
HF risk, include the pro-oxidant and pro-inflammatory properties of GGT (67), as well as its 
direct involvement in atheromatous plaque formation (68). Other pathways implicated 
include underlying fatty liver (67) (which is associated with low-grade inflammation, insulin 
resistance, and oxidative stress (86, 87)); endothelial dysfunction; and exposure to 
environmental pollutants (88, 89). 
 
Cardiac arrhythmias 
Until recently, there was uncertainty as to whether GGT was associated with cardiac 
arrhythmias. Alonso and colleagues in the Atherosclerosis Risk in Communities (ARIC) 
study reported a positive, linear, and independent association between GGT activity and risk 
of atrial fibrillation (AF) (90). Our group has also recently shown a positive log-linear 
association of GGT with risk of AF in age-adjusted analysis, but which was attenuated on 
further adjustment for conventional risk factors (85). In the same study, we also demonstrated 
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a positive log-linear association between GGT and ventricular arrhythmias in analyses 
adjusted for established vascular risk factors, but the association was attenuated on further 
adjustment for other potential confounders. Putative biological mechanisms accounting for 
the associations include oxidative and inflammatory pathways (67), direct involvement of 
GGT in atheromatous plaque formation (68), fatty liver (67), and endothelial dysfunction and 
exposure to environmental pollutants (88, 89). Given the limited evidence available, further 
large-scale prospective studies are warranted to assess the associations and to evaluate 
whether measurement of GGT activity can usefully contribute to risk prediction algorithms 
for cardiac arrhythmias. 
 
Sudden cardiac death 
In analyses of the Kuopio Ischemic Heart Disease (KIHD) prospective cohort study of 1,780 
men aged 42-61 years that recorded 136 sudden cardiac deaths (SCDs) during 22 years of 
follow-up, we have shown for the first time that GGT is positively, log-linearly, and 
independently associated with future risk of SCD (83). The association was not importantly 
modified under different circumstances (such as by age, smoking status, or different levels of 
established vascular risk factors). As postulated previously, the pro-inflammatory activities of 
GGT (67) and its direct involvement in atheromatous plaque formation (68, 72) may underlie 
the association. Nonalcoholic fatty liver disease which is associated with cardiac autonomic 
dysfunction (a risk factor for SCD) (91), may also be mediating the association. Whether 
GGT has any clinical use in improving SCD risk prediction is yet to be investigated. 
 
Type 2 diabetes mellitus 
The first prospective study to examine the association between GGT and incident T2DM was 
reported in 1998 (92). Since then, several studies have evaluated the associations between 
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GGT and T2DM risk, but reported apparently conflicting results. To put the data into context 
and provide a better indication of the relevance of GGT to T2DM risk, Fraser and colleagues 
in a meta-analysis of 13 prospective studies showed a positive and independent association 
between GGT and T2DM risk (Table and Figure 2) (93). Given the uncertainty regarding 
the shape of the GGT-T2DM association, our group conducted an updated meta-analysis 
which included 24 prospective cohort studies and showed that GGT contributes to an 
increased risk of T2DM in a nonlinear dose-response pattern (94). A graded increase in 
T2DM risk was evident at GGT levels 9-35 U/L, with the effects of GGT seeming to level off 
beyond 35 U/L. Ballestri and colleagues in a meta-analysis of nine studies evaluating the 
prospective association between NAFLD (as diagnosed by elevated GGT activity) and 
T2DM, demonstrated an almost two-fold increase in the risk of incident T2DM (95).  
Gamma-glutamyltransferase has been postulated to be linked to the development of T2DM 
via oxidative stress, increased inflammation and underlying fatty liver (NAFLD), which are 
major pathways in the pathophysiology of T2DM (95-97). The causal relevance of GGT to 
T2DM is still yet to be investigated and current evidence suggests that serum GGT provides 
little incremental benefit for prediction of T2DM risk (98, 99).  
 
Metabolic syndrome 
In a review of nine prospective cohort studies, Liu and colleagues reported a positive and 
independent association between GGT and the MetS (Table and Figure 2) (100). In an 
updated meta-analysis of 10 studies, we showed a nonlinear relationship (albeit using limited 
published data) to the positive association which was evident within normal reference values 
of GGT (101). In pooled analysis of five studies, Ballestri and colleagues reported NAFLD to 
be associated with a two-fold increase in the risk of incident T2DM, when elevated GGT 
activity was used as an indicator of NAFLD (95). Mechanistic pathways underlying the 
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relationship between GGT and the MetS have been linked to similar processes suggested for 
GGT and T2DM; which include oxidative stress, increased inflammation and excessive 
deposition of fat in the liver, all of which are implicated in impaired insulin signalling and 
insulin resistance (32, 102). The relationships between GGT activity and the MetS as well as 
its components, have been attributed to genetic origins. Loomba and colleagues using a twin 
study design, reported genetic covariance between GGT and MetS traits such as insulin 
resistance, increased triglycerides, and blood pressure (103). The adrenergic locus ADRB2 
was also shown to have pleiotropic effects on both circulating GGT and triglycerides. 
 
Hypertension 
In a meta-analysis of 13 prospective cohort studies, Liu and colleagues reported a positive 
association between GGT activity and hypertension risk (Table and Figure 2) (104). In an 
updated meta-analysis of 14 studies, we showed an approximately 30% increased risk of 
future hypertension when comparing individuals in the top versus bottom thirds of circulating 
GGT values and this was consistent with a linear dose-response relationship (105). Elevated 
GGT activity has been suggested to signify states of oxidative stress, increased inflammation, 
and fatty liver, consequently leading to impaired insulin secretion and insulin resistance, all 
of which have been implicated in the development of hypertension (106, 107).  
 
Cancer 
Gamma-glutamyltransferase has also been linked to the risk of cancer. Long and colleagues 
in a review of available prospective epidemiological data suggested a positive association 
between GGT and cancer-related mortality (60). However, a pooled analysis was not 
conducted which precluded assessment of the magnitude of the association. In a meta-
analyses of 10 cohort studies involving 780,553 participants and 52,724 cancer events, we 
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have shown a positive association between GGT and overall cancer outcomes and which was 
also consistent with a log-linear relationship (108) (Table and Figure 2). Significant positive 
associations for site-specific cancers such as breast cancer, cancers of male genital organs, 
cancers of digestive organs, and liver cancer were also reported in this study. In a subgroup 
analyses, the associations were consistent across several study characteristics including 
incident cancers and cancer mortality. In a pooled analysis of two population-based cohorts 
comprising a total of 107,058 participants, Preyer and colleagues reported a significantly 
higher risk of breast cancer comparing the top versus bottom quartile of GGT values (109). 
Whether GGT has a direct aetiological role in carcinogenesis or just a risk marker of an 
underlying aetiology is uncertain. It has however been postulated that the persistent 
production of reactive oxygen species (ROS) from GGT-mediated metabolism may 
contribute to tumour progression; as low levels of ROS have been suggested to modulate a 
range of biological responses involved in cellular growth, proliferation, and apoptosis (110, 
111). Gamma-glutamyltransferase activity has also been considered to confer rapid turnover 
and survival advantages for cancer cells.(112) A number of experimental studies have also 
suggested a direct causative role of GGT in carcinogenesis (110, 113). The association 
between GGT and liver cancers, may also reflect underlying NAFLD, which itself is an 
important risk factor for HCC (54). 
 
Chronic kidney disease 
In the first prospective evaluation of GGT and CKD, Ryu and colleagues employed a large 
cohort of 10,337 nonhypertensive and nondiabetic Korean male workers with normal kidney 
function at baseline, and demonstrated increased GGT activity to be significantly associated 
with an increased risk of future CKD in a nonlinear fashion (109). The association remained 
consistent on adjustment for a comprehensive panel of confounders and mediators. The 
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authors speculated several mechanistic pathways to underlie the association between GGT 
and CKD; some of which include alcohol consumption, liver disease, obesity, insulin 
resistance, and low-grade inflammation. However, since all these factors were accounted for 
in their multivariate analyses, the authors reported that it was highly unlikely that these 
pathways were involved in the pathophysiology. Based on the broad body of evidence 
demonstrating GGT as a marker of oxidative stress, it was suggested that the association of 
GGT with risk of CKD might be due to mechanisms related to oxidative stress (69). It has 
been reported that renal ROS cause vasoconstriction of renal vasculature, leading to sodium 
retention and subsequently renal damage (114, 115). Targher and colleagues in a recent study 
reviewed evidence on the link between NAFLD and CKD. It was postulated that the origins 
for this relationship were via pathways such as atherogenic dyslipidemia, insulin resistance, 
dysglycemia, and the release of pro-inflammatory, pro-coagulant, and pro-fibrogenic factors, 
which cause kidney damage (55). Given the strong relationship between NAFLD and GGT 
activity, NAFLD may mediate the association between GGT and CKD. Because of the 
limited evidence on the GGT-CKD relationship, further studies are needed to replicate this 
association especially among female populations. 
 
Fractures 
Gamma-glutamyltransferase has been demonstrated to have harmful effects on bone 
metabolism in in vitro studies and animal models (116, 117). In the first epidemiological data 
involving humans, a large prospective study involving 16,036 Korean men with an average 
follow-up of 3 years, demonstrated a higher serum GGT activity to be independently 
associated with an increased risk of osteoporotic fractures. Aetiopathogenic pathways 
suggested to underlie the association between GGT and risk of fractures include oxidative 
stress, inflammation, and a direct pathogenic role of GGT in metabolic bone diseases. 
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Oxidative stress has been shown to have adverse effects on bone metabolism (118, 119). An 
in vitro study has shown GGT to induce the formation of osteoclasts, independent of its 
enzymatic activity, via stimulation of the receptor activator of nuclear factor-kappaB ligand 
expression (116). An animal study has also shown that GGT overexpression accelerates bone 
resorption and causes osteoporosis (117). 
 
Dementia 
GGT has recently been shown to be positively, log-linearly, and independently associated 
with future risk of dementia in a population-based cohort of 2,415 apparently healthy men 
with good cognitive function from eastern Finland (120). This association remained robust in 
several sensitivity analyses. Since mechanistic research provides strong support for 
inflammatory and oxidative processes in the aetiogenesis of dementia (121-123), it was 
proposed that GGT might contribute to the development of dementia via its pro-inflammatory 
and pro-oxidant properties (67). In addition, since NAFLD has been linked to the 
pathogenesis of cognitive impairment via insulin resistance,(124) there is a possibility that 
underlying NAFLD may be a link between the observed association. Being the only 
longitudinal study so far to report on this association, further research is needed to replicate 
these findings and help unravel the mechanistic pathways of GGT in the pathogenesis of 
dementia. 
 
All-cause mortality 
Finally, GGT has also been linked to the risk of all-cause mortality, an outcome which has 
been suggested to be a more ultimate indicator of health than cause-specific outcomes (125). 
In a meta-analysis of three prospective cohort studies, Du and colleagues showed a positive 
association of GGT with all-cause mortality comparing the highest versus lowest GGT 
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quartile (Table and Figure 2) (59). Long and colleagues in their review also reported a 
positive association between GGT and all-cause mortality (60). In the most recent review, 
pooled analysis of 11 prospective cohorts (comprising over 9 million participants and 
236,765 all-cause mortality outcomes) also showed a positive association between GGT and 
all-cause mortality which was consistent with a linear dose-response relationship (126). 
Increased mortality risk associated with GGT has been suggested to be mediated by increased 
cardiovascular risk via pathways reported above. 
 
Management of asymptomatic individuals with isolated raised GGT values 
As there are established published clinical guidelines for the management of liver enzymes 
including GGT, this section is not intended as a comprehensive management guide for 
elevated GGT. In light of the current overall evidence, there is a possibility that GGT may 
only be a risk marker for these adverse outcomes. It therefore appears the clinical 
implications for these findings are elusive. However, despite the limited role of GGT in 
disease risk prediction and absence of data showing any causal relevance to these adverse 
outcomes, the preceding observations may be translated into clinical improvements. Assays 
for GGT may have the potential to aid in the identification of individuals at moderate to high 
risk of these adverse outcomes. Gamma-glutamyltransferase assays are sensitive, well 
standardized, simple, inexpensive, and commonly measured as part of routine liver 
biochemistry panels. Though GGT is not very specific for the liver, mild and subtle 
elevations in GGT values below the upper limits of normal are very common in the general 
population and may indicate the presence of subclinical liver disease. Patients with isolated 
elevated values (even within normal reference ranges) of GGT should be considered for 
further evaluation. Factors which are associated with elevated GGT (such as increased BMI, 
alcohol consumption, smoking, and medication use) as discussed in a previous section, 
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should be assessed for in the individual. Nonalcoholic fatty liver disease should also be 
suspected and screened for, especially in those with increased body weight and associated 
factors; though NAFLD may rarely be a cause of isolated raised GGT activity. Patients 
diagnosed with or suspected of having NAFLD should be screened for T2DM, given their 
close inter-relationship. Many patients with increased GGT activity will also have risk factors 
for vascular disease and other chronic diseases, which should be assessed and such patients 
should have their disease risk assessed using established risk engines. Patients identified to 
have factors (e.g., NAFLD, excessive smoking and alcohol consumption, obesity) accounting 
for elevated GGT values, should be provided with lifestyle advice on healthy eating, physical 
activity, weight loss, smoking cessation, and reduction in alcohol intake. Several studies (75, 
127, 128) have found evidence to support a substantial lowering effect of a variety of 
interventions (including lifestyle-related factors such as sustained weight loss (128), physical 
activity, and dietary factors (127)) on circulating GGT activity. On implementation of these 
lifestyle changes, patients should have repeat liver biochemical tests in a few months for 
reassessment by the clinician. Patients with persistently elevated values not amenable to 
lifestyle advice should be considered for specialist referral. 
 
Conclusion 
Gamma-glutamyltransferase, a liver enzyme, which plays an important role in cellular 
defence and protection of cells against further oxidative stress; is linked to a remarkable array 
of chronic diseases as well as all-cause mortality outcomes. It has been consistently 
demonstrated that increased GGT activity (sometimes within normal reference values) is 
positively associated with each of the outcomes reviewed, with majority of these associations 
consistent with linear relationships. Plentiful putative mechanistic pathways underlying these 
associations have been proposed, but many of these are hypothetical and are not well 
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understood. Undoubtedly, increased GGT activity is associated with adverse levels of 
classical vascular risk factors. However, though a large and broadly consistent body of 
evidence has established GGT as moderately to strongly linked to the development of these 
vascular and non-vascular outcomes, its role in the causal pathways for these outcomes is 
uncertain and current evidence (albeit limited) suggests that serum GGT is unlikely to 
improve disease risk prediction beyond established risk factors. Further work, however, is 
crucially needed to understand the pathophysiological mechanisms that underlie the 
associations between GGT and these adverse outcomes; establish any causal relevance to the 
associations; and whether these could be translated into clinical benefits. 
 
Data sources and selection criteria 
Relevant prospective cohort studies (with at least one year of follow-up) conducted in general 
populations were sought from MEDLINE, EMBASE, and Web of Science; with particular 
emphasis on systematic reviews and meta-analyses of these study designs. Search terms 
included “gamma-glutamyltransferase”, “nonalcoholic fatty liver disease”, “cardiovascular 
disease”, “coronary heart disease”, “diabetes”, “metabolic syndrome”, “hypertension”, 
“cancer”, “chronic kidney disease”, “fracture”, “dementia”, and “mortality”. Studies were 
limited to those in adults and written in English. 
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Table. Available meta-analyses of prospective studies of gamma-glutamyltransferase and 
adverse outcomes 
Author, year of 
publication 
[reference] 
No. of 
studies 
Outcome No. of 
participants 
No. of 
cases 
Combined risk 
(95% CI) 
Risk comparison 
reported 
       
Fraser, 2007 [57] 
 
11 
7 
6 
CVD 
CHD 
Stroke 
1,017,231 
998,906 
976,877 
12,365 
5,283 
4,682 
1.34 (1.22-1.48) 
1.20 (1.02-1.40) 
1.54 (1.19-1.99) 
Per 1 U/L change 
Per 1 U/L change 
Per 1 U/L change 
Kunutsor, 2014 [58] 20 
9 
9 
CVD 
CHD 
Stroke 
1,054,181 
1,006,176 
825,255 
15,194 
4,570 
4,738 
1.23 (1.16-1.29) 
1.17 (1.00-1.36) 
1.28 (1.10-1.50) 
Per 1 SD change 
Per 1 SD change 
Per 1 SD change 
Du, 2013 [59] 5 CVD mortality 192,461 4,866 1.52 (1.36-1.70) Top versus bottom 
fourth 
Long, 2014 [60]  CVD mortality 253,555 7,213 1.60 (1.48-1.73) Highest versus lowest 
category 
Zhang, 2015 [61] 10 Stroke 926,497 5,707 1.28 (1.16-1.43) Highest versus lowest 
category 
Kunutsor, 2016 [85] 5 Heart failure 210,841 1,821 1.28 (1.20-1.35)  
 
1.43 (1.31-1.56)  
Per 1 SD change in 
baseline values 
Per 1 SD change in 
usual vales 
Kunutsor, 2016 [85] 2 Atrial fibrillation 11,113 1,357 1.09 (1.02-1.16) 
 
1.14 (1.03-1.25) 
Per 1 SD change in 
baseline values 
Per 1 SD change in 
usual values 
Fraser, 2009 [93] 13 T2DM 62915 2732 1.92 (1.66-2.21) Per 1 U/L change 
Kunutsor, 2014 [94] 24 T2DM 177,307 11,155 1.34 (1.27-1.42) Top versus bottom 
third 
Ballestri, 2016 [95] 9 T2DM 2,006 32,170 1.86 (1.71-2.03) Highest versus lowest 
category 
Liu, 2012 [100] 9 MetS 47,499 5,009 1.63 (1.43-1.82) Highest versus lowest 
category 
Kunutsor, 2014 [101] 10 MetS 67,905 6,595 1.88 (1.49-2.38) Top versus bottom 
third 
Ballestri, 2016 [95] 9 MetS 5,706 69,840 1.98 (1.89-2.07) Highest versus lowest 
category 
Liu, 2012 [104] 13 Hypertension 43,314 5,280 1.94 (1.55-2.43) Highest versus lowest 
category 
Kunutsor, 2015 [105] 14 Hypertension 44,582 5,270 1.32 (1.23-1.43) Top versus bottom 
third 
Kunutsor, 2015 [108] 10 Cancer 780,553 52,724 1.32 (1.15-1.52) Top versus bottom 
third 
Du, 2013 [59] 3 All-cause 
mortality 
19,241 2,235 1.56 (1.34-1.83) Top versus bottom 
fourth 
Long, 2014 [60]  All-cause 
mortality 
47,837 7,523 1.75 (1.47-2.08) Highest versus lowest 
category 
Kunutsor, 2014 [126] 11 All-cause 
mortality 
9,071,005 236,765 1.60 (1.42-1.80) Top versus bottom 
third 
 
CHD, coronary heart disease; CVD, cardiovascular disease; MetS, metabolic syndrome; SD, standard deviation; 
T2DM, type 2 diabetes mellitus 
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Figure legends 
 
Figure 1. Median serum GGT values in the general population by gender and age groups 
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GGT, gamma-glutamyltransferase; Data for the figure was extracted from Schiele F, Guilmin 
AM, Detienne H, Siest, G. Gamma-glutamyltransferase activity in plasma: statistical 
distributions, individual variations, and reference intervals. Clin Chem. 1977; 23: 1023–8. 
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Figure 2. Forest plot of available meta-analyses of prospective studies of gamma-
glutamyltransferase and adverse outcomes 
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Author, year of publication
[Reference]
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7
6
20
9
9
5
8
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5
2
13
24
9
9
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5
13
14
10
3
5
11
No. of studies
12,365
5,283
976,877
15,194
4,570
4,738
4,866
7,213
5,707
1,821
1,357
2,732
11,155
2,006
5,009
6,595
5,706
5,280
5,270
52,724
2,235
47,837
236,765
No. of cases
1017231
998,906
4,682
1054181
1006176
825,255
192,461
253,555
926,497
210,841
11,113
62,915
177,307
32,170
47,499
67,905
69,840
43,314
44,582
780,553
19,241
7,523
9071005
No. of total participants
1.53 (1.33, 1.77)
1.31 (1.04, 1.65)
1.88 (1.29, 2.74)
1.49 (1.30, 1.71)
1.41 (1.01, 1.97)
1.71 (1.22, 2.40)
1.43 (1.30, 1.58)
1.60 (1.48, 1.73)
1.28 (1.16, 1.43)
1.71 (1.51, 1.95)
1.21 (1.05, 1.39)
2.59 (2.11, 3.20)
1.34 (1.27, 1.42)
1.86 (1.71, 2.03)
1.63 (1.43, 1.82)
1.88 (1.49, 2.38)
1.98 (1.89, 2.07)
1.94 (1.55, 2.43)
1.32 (1.23, 1.43)
1.32 (1.15, 1.52)
1.46 (1.28, 1.67)
1.75 (1.47, 2.08)
1.60 (1.42, 1.80)
RR (95% CI)
CVD
CHD
Stroke
CVD
CHD
Stroke
CVD mortality
CVD mortality
Stroke
Heart failure
Atrial fibrillation
T2DM
T2DM
T2DM
MetS
MetS
MetS
Hypertension
Hypertension
Cancer
All-cause mortality
All-cause mortality
All-cause mortality
Outcome
1.5 1.5 2.5 5
RR (95% CI) Top versus bottom third of GGT values
 
 
CHD, coronary heart disease; CI, confidence interval; CVD, cardiovascular disease; GGT, 
gamma-glutamyltransferase; MetS, metabolic syndrome; RR, relative risk; SD, standard 
deviation; T2DM, type 2 diabetes mellitus 
Relative risks were converted to “top versus bottom thirds of GGT values” where 
appropriate, to ensure consistency and enhance comparison; *, denotes studies where authors 
reported a risk comparison of “highest versus bottom category of GGT values” which could 
not be converted. 
 
 
